Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics.

Find annual and quearterly earnings data for Dragonfly Energy Holdings Corp. Common Stock (NV) (DFLI) including earnings per share, earnings forecasts at Nasdaq.com.